Artera has announced U.S. Food and Drug Administration clearance for ArteraAI Breast, a digital pathology-based risk stratification tool designed for patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer. This marks the first FDA-cleared tool of its kind in breast cancer and expands the company’s multimodal artificial intelligence (MMAI) platform into a second major oncology indication following prostate cancer.
The clearance builds on Artera’s growing regulatory presence, which includes prior FDA authorization for its prostate cancer solution and recent CE Marking for both its prostate and breast cancer assays in Europe. These developments reflect the company’s strategy to scale its AI-driven precision medicine platform across multiple geographies and cancer types.
“FDA clearance for ArteraAI Breast represents a significant expansion of our FDA-cleared AI platform in oncology,” said Andre Esteva, CEO and co-founder of Artera. “This milestone reflects the growing role of our technology across multiple cancer types. Breast cancer care is highly nuanced, with treatment decisions that depend on individualized risk. Our goal remains consistent across prostate and breast cancer, and beyond: to help clinicians translate complex data into more precise, personalized treatment decisions across the cancer journey.”
ArteraAI Breast generates an AI-derived risk score that evaluates the likelihood of distant metastasis in patients at the time of diagnosis. By combining digitized histopathology images with patient clinical data, the system stratifies patients into low- and high-risk categories based on a predefined threshold. This approach is intended to support clinicians in determining the appropriate intensity of therapy in cases where clinical and pathological factors vary significantly.
Clinical validation data presented at the 2025 San Antonio Breast Cancer Symposium indicated that the model may help inform chemotherapy benefit for certain patient subgroups. The tool is designed to integrate into standard pathology workflows using routine surgical resection samples, eliminating the need for additional tissue collection and enabling same-day reporting.
“This clearance represents an important advance on the road to personalizing treatments for patients with early-stage breast cancer,” said Eric Winer, MD, medical oncologist and director of the Yale Cancer Center. “Using AI and digital pathology has the potential to streamline operational workflows, while creating a strong interdisciplinary linkage between oncology and pathology. This approach may further improve the clinicians' ability to help patients make the best treatment decisions.”
Artera’s MMAI platform has been validated in multiple Phase 3 randomized trials and continues to expand globally, supporting clinical decision-making through integrated prognostic and predictive insights.
Click here for the original news story.
